Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Dallas VA Medical Center

Status: Completed

Conditions: Colonoscopy; Anti-platelet Therapy; Post-polypectomy Bleeding

Study type: Observational

Funder types: Other U.S. Federal agency

Identifiers

NCT01647568

DVAMC-09-084

Details and patient eligibility

About

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Enrollment: 715 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients presenting to the GI lab for elective colonoscopy

Exclusion criteria

• Patients on Coumadin or other anti-coagulants
• Patients with Inflammatory Bowel Disease

Trial design

715 participants in 2 patient groups

Control

Description:

Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.

Thienopyridine Users

Description:

Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.